Autosomal Dominant Polycystic Kidney Disease

The incidence of asymptomatic pyuria is correlated with rapid decline in kidney function irrespective of the autosomal dominant polycystic kidney disease genotype and cystic growth.

Each year, millions of Americans take charge of their health by visiting their primary care provider for a periodic “check-up” or health maintenance visit.

Measuring urine-to-plasma urea ratio in the early morning was “the best representative of the urine-concentrating capacity” and predicted kidney function decline in patients with autosomal dominant polycystic kidney disease.

For patients with autosomal dominant polycystic kidney disease, undergoing bilateral nephrectomy and kidney transplantation in the same sitting led to cost savings and shorter hospital stays.

Kidney Disease: Improving Global Outcomes is developing a new guideline for the treatment of patients with autosomal dominant polycystic kidney disease, according to a press release from the organization. The process could take up to 2 years.

Patients with autosomal dominant polycystic kidney disease who had mutations in two specific genes were more likely to respond favorably to treatment with tolvaptan than those who showed no mutations.

A study from the Netherlands indicated higher consumption of salt was associated with accelerated disease progression for patients with autosomal dominant polycystic kidney disease. This effect was not seen with higher protein intake.

Treatment with tolvaptan did not appear to affect health-related quality of life for Swiss patients with autosomal-dominant polycystic kidney disease, according to study results.

The PKD Foundation has launched a new patient registry as part of Polycystic Kidney Disease Awareness Day, held on Sept. 4.